サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1664608

血漿タンパク質治療薬の世界市場レポート 2025年

Plasma Protein Therapeutics Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血漿タンパク質治療薬の世界市場レポート 2025年
出版日: 2025年02月27日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血漿タンパク質治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.6％で463億5,000万米ドルに成長します。予測期間の成長は、遺伝子治療の進歩、ヘルスケア支出の増加、適応症の拡大、精密医療アプローチ、患者アクセスプログラムに起因すると考えられます。予測期間の主な動向には、技術革新、遠隔医療の採用、血漿分画の技術進歩、次世代療法の開発、組み換え療法の採用、個別化医療アプローチなどがあります。

自己免疫疾患の有病率の上昇は、今後の血漿タンパク質治療薬市場の成長を促進すると予測されています。自己免疫疾患は、身体の免疫システムが誤って健康な細胞を攻撃し、破壊することで発生します。治療的血漿交換はこれらの疾患に用いられる治療法であり、身体が誤って自身の一部を異物と認識し、この誤認識された部位を標的とする自己抗体と呼ばれるタンパク質を産生します。例えば、2023年5月、英国の公立大学であるUniversity of Glasgowが2,200万人を対象に実施した研究によると、自己免疫疾患は英国人口の約10％が罹患していることが明らかになり、これまでの推定を上回りました。このように、自己免疫疾患の罹患率の増加が、血漿タンパク質治療薬市場の今後の成長を後押ししています。

血漿タンパク質治療薬市場の成長は、慢性疾患の有病率の増加によって促進されると予想されます。慢性疾患は1年以上続き、継続的な医療を必要とするため、日常生活に大きな影響を与えます。血漿タンパク質治療薬は、欠乏症に対処し、免疫システムを調整し、様々な生理学的機能をサポートすることにより、慢性疾患の管理に重要な役割を果たしています。2022年9月の世界保健機関（WHO）のデータによると、非伝染性疾患（NCDs）または慢性疾患は、世界全体での年間死亡者数4,100万人のうち74％を占めています。心血管疾患、がん、慢性呼吸器疾患、糖尿病がこの統計に大きく寄与しています。したがって、慢性疾患の有病率の増加が血漿タンパク質治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の血漿タンパク質治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の血漿タンパク質治療薬市場：成長率分析
  • 世界の血漿タンパク質治療薬市場の実績：規模と成長、2019～2024年
  • 世界の血漿タンパク質治療薬市場の予測：規模と成長、2024～2029年、2034年
  • 世界の血漿タンパク質治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の血漿タンパク質治療薬市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
  • 免疫グロブリン
  • アルブミン
  • 凝固因子
  • C1エステラーゼ阻害剤
  • その他
  • 世界の血漿タンパク質治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 静脈内
  • 皮下
  • 世界の血漿タンパク質治療薬市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • 原発性免疫不全症（PID）
  • 特発性血小板減少性紫斑病
  • 二次免疫不全症
  • 遺伝性血管性浮腫
  • その他
  • 世界の血漿タンパク質治療薬市場：免疫グロブリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 静脈内免疫グロブリン（IVIG）
  • 皮下免疫グロブリン（SCIG）
  • 世界の血漿タンパク質治療薬市場：アルブミンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ヒト血清アルブミン
  • 遺伝子組み換えアルブミン
  • 世界の血漿タンパク質治療薬市場：凝固因子のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 第VIII因子
  • 第IX因子
  • プロトロンビン複合体濃縮物
  • 世界の血漿タンパク質治療薬市場：C1エステラーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ヒトC1エステラーゼ阻害剤
  • 遺伝子組み換えC1エステラーゼ阻害剤
  • 世界の血漿タンパク質治療薬市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • フィブリノーゲン
  • α1アンチトリプシン
  • 凝固因子濃縮物

第7章 地域別・国別分析

  • 世界の血漿タンパク質治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の血漿タンパク質治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 血漿タンパク質治療薬市場：競合情勢
  • 血漿タンパク質治療薬市場：企業プロファイル
    • CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
    • Grifols SA Overview, Products and Services, Strategy and Financial Analysis
    • China Biologic Products Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Kedrion SpA
  • LFB SA
  • Emergent BioSolutions Inc.
  • Reliance Life Sciences Private Limited
  • ADMA Biologics Inc.
  • Prothya Biosolutions BV
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • Taibang Biological Group Co Ltd
  • Octapharma Plasma Inc.
  • New York Blood Center
  • Green Cross Corporation
  • China National Biotec Group Company Limited
  • Kamada Ltd.
  • Australian Red Cross Lifeblood

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 血漿タンパク質治療薬市場2029年：新たな機会を提供する国
  • 血漿タンパク質治療薬市場2029年：新たな機会を提供するセグメント
  • 血漿タンパク質治療薬市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r23650

Plasma protein therapeutics involves treatments derived from plasma and their recombinant counterparts, designed to address specific medical conditions by replacing deficient or missing proteins present in plasma. This enables recipients to lead healthier and more productive lives.

The primary products within plasma protein therapeutics include immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other related products. Immunoglobulin constitutes a component of blood plasma containing antibodies, and it is administered through various routes such as intravenous and subcutaneous. These treatments find applications in addressing conditions such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and various other medical needs.

The plasma protein therapeutics market research report is one of a series of new reports from The Business Research Company that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasma protein therapeutics market size has grown strongly in recent years. It will grow from $31.86 billion in 2024 to $34.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of rare diseases, growing aging population, global blood plasma supply, rise in hemophilia cases, improvements in diagnosis, supportive regulatory environment.

The plasma protein therapeutics market size is expected to see strong growth in the next few years. It will grow to $46.35 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to gene therapy advancements, increasing healthcare expenditure, expanded indications, precision medicine approaches, patient access programs. Major trends in the forecast period include technological innovations, telemedicine adoption, technological advancements in plasma fractionation, development of next-generation therapies, adoption of recombinant therapies, personalized medicine approaches.

The rising prevalence of autoimmune disorders is anticipated to drive the growth of the plasma protein therapeutics market in the future. Autoimmune disorders occur when the body's immune system mistakenly attacks and destroys healthy cells. Therapeutic plasma exchange is a treatment used for these diseases, wherein the body incorrectly identifies part of itself as foreign and produces proteins called autoantibodies that target these misidentified areas. For instance, in May 2023, a study conducted by the University of Glasgow, a public university in the UK, involving 22 million people, revealed that autoimmune disorders affect approximately 10% of the UK population, surpassing previous estimates. Thus, the increasing incidence of autoimmune disorders is propelling the growth of the plasma protein therapeutics market moving forward.

The growth of the plasma protein therapeutics market is expected to be propelled by the increasing prevalence of chronic diseases. Chronic diseases, lasting a year or longer and requiring ongoing medical care, significantly impact daily activities. Plasma protein therapeutics play a crucial role in managing chronic diseases by addressing deficiencies, modulating the immune system, and providing support for various physiological functions. According to the World Health Organization's data from September 2022, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million deaths globally each year. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this statistic. Therefore, the growing prevalence of chronic diseases is driving the growth of the plasma protein therapeutics market.

Product innovations are emerging as a significant trend in the plasma protein therapeutics market. Major companies in this sector are concentrating on developing innovative products to secure a competitive edge. For example, in October 2023, Octapharma AG, a Switzerland-based company, received approval from European medical authorities for the lyophilized version of its well-known product, octaplasLG. This advanced formulation is intended for pre-hospital transfusions, offering healthcare professionals a convenient and effective option for managing patients in critical conditions. This approval highlights Octapharma's dedication to improving patient care through innovative solutions in the blood products arena.

Strategic collaborations are playing a crucial role in the plasma protein therapeutics market. Major companies are entering partnerships to enhance their product portfolios, extend global reach, and drive innovation in new therapy development. For instance, LFB Plasma, a US-based plasma collection company, announced a collaboration with the Plasma Protein Therapeutics Association (PPTA) in September 2022. This strategic partnership is aimed at expanding LFB Plasma's presence in the US and reinforcing its commitment to both plasma donors and patients.

In April 2022, Grifols S.A., a Spain-based pharmaceutical and chemical manufacturer, acquired Tiancheng (Germany) Pharmaceutical Holdings AG for €1.6 billion ($1.72 billion). This acquisition is expected to accelerate and broaden Grifols' product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Tiancheng (Germany) Pharmaceutical Holdings AG, also known as Biotest, is a Germany-based healthcare company specializing in innovative hematology and clinical immunology, focusing on the development, manufacturing, and marketing of plasma proteins and biotherapeutic drugs.

Major companies operating in the plasma protein therapeutics market include CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., New York Blood Center, Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Australian Red Cross Lifeblood

North America was the largest region in the plasma protein therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plasma Protein Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plasma protein therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for plasma protein therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasma protein therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Immunoglobulin; Albumin; Coagulation Factor; C1-esterase Inhibitors; Other Products
  • 2) By Route Of Administration: Intravenous; Subcutaneous
  • 3) By Applications: Primary Immunodeficiency Disorder (PID); Idiopathic Thrombocytopenic Purpura; Secondary Immunodeficiency; Hereditary Angioedema; Other Applications
  • Subsegments:
  • 1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG); Subcutaneous Immunoglobulin (SCIG)
  • 2) By Albumin: Human Serum Albumin; Recombinant Albumin
  • 3) By Coagulation Factor: Factor VIII; Factor IX; Prothrombin Complex Concentrates
  • 4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors; Recombinant C1-Esterase Inhibitors
  • 5) By Other Products: Fibrinogen; Alpha-1 Antitrypsin; Clotting Factor Concentrates
  • Companies Mentioned: CSL Behring LLC; Grifols SA; China Biologic Products Holdings Inc.; Takeda Pharmaceutical Company Limited; Baxter International Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Plasma Protein Therapeutics Market Characteristics

3. Plasma Protein Therapeutics Market Trends And Strategies

4. Plasma Protein Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Plasma Protein Therapeutics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Plasma Protein Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Plasma Protein Therapeutics Market Growth Rate Analysis
  • 5.4. Global Plasma Protein Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Plasma Protein Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Plasma Protein Therapeutics Total Addressable Market (TAM)

6. Plasma Protein Therapeutics Market Segmentation

  • 6.1. Global Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunoglobulin
  • Albumin
  • Coagulation Factor
  • C1-esterase Inhibitors
  • Other Products
  • 6.2. Global Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous
  • Subcutaneous
  • 6.3. Global Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Immunodeficiency Disorder (PID)
  • Idiopathic Thrombocytopenic Purpura
  • Secondary Immunodeficiency
  • Hereditary Angioedema
  • Other Applications
  • 6.4. Global Plasma Protein Therapeutics Market, Sub-Segmentation Of Immunoglobulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
  • 6.5. Global Plasma Protein Therapeutics Market, Sub-Segmentation Of Albumin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Human Serum Albumin
  • Recombinant Albumin
  • 6.6. Global Plasma Protein Therapeutics Market, Sub-Segmentation Of Coagulation Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Factor VIII
  • Factor IX
  • Prothrombin Complex Concentrates
  • 6.7. Global Plasma Protein Therapeutics Market, Sub-Segmentation Of C1-Esterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Human C1-Esterase Inhibitors
  • Recombinant C1-Esterase Inhibitors
  • 6.8. Global Plasma Protein Therapeutics Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fibrinogen
  • Alpha-1 Antitrypsin
  • Clotting Factor Concentrates

7. Plasma Protein Therapeutics Market Regional And Country Analysis

  • 7.1. Global Plasma Protein Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Plasma Protein Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Plasma Protein Therapeutics Market

  • 8.1. Asia-Pacific Plasma Protein Therapeutics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Plasma Protein Therapeutics Market

  • 9.1. China Plasma Protein Therapeutics Market Overview
  • 9.2. China Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Plasma Protein Therapeutics Market

  • 10.1. India Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Plasma Protein Therapeutics Market

  • 11.1. Japan Plasma Protein Therapeutics Market Overview
  • 11.2. Japan Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Plasma Protein Therapeutics Market

  • 12.1. Australia Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Plasma Protein Therapeutics Market

  • 13.1. Indonesia Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Plasma Protein Therapeutics Market

  • 14.1. South Korea Plasma Protein Therapeutics Market Overview
  • 14.2. South Korea Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Plasma Protein Therapeutics Market

  • 15.1. Western Europe Plasma Protein Therapeutics Market Overview
  • 15.2. Western Europe Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Plasma Protein Therapeutics Market

  • 16.1. UK Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Plasma Protein Therapeutics Market

  • 17.1. Germany Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Plasma Protein Therapeutics Market

  • 18.1. France Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Plasma Protein Therapeutics Market

  • 19.1. Italy Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Plasma Protein Therapeutics Market

  • 20.1. Spain Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Plasma Protein Therapeutics Market

  • 21.1. Eastern Europe Plasma Protein Therapeutics Market Overview
  • 21.2. Eastern Europe Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Plasma Protein Therapeutics Market

  • 22.1. Russia Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Plasma Protein Therapeutics Market

  • 23.1. North America Plasma Protein Therapeutics Market Overview
  • 23.2. North America Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Plasma Protein Therapeutics Market

  • 24.1. USA Plasma Protein Therapeutics Market Overview
  • 24.2. USA Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Plasma Protein Therapeutics Market

  • 25.1. Canada Plasma Protein Therapeutics Market Overview
  • 25.2. Canada Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Plasma Protein Therapeutics Market

  • 26.1. South America Plasma Protein Therapeutics Market Overview
  • 26.2. South America Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Plasma Protein Therapeutics Market

  • 27.1. Brazil Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Plasma Protein Therapeutics Market

  • 28.1. Middle East Plasma Protein Therapeutics Market Overview
  • 28.2. Middle East Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Plasma Protein Therapeutics Market

  • 29.1. Africa Plasma Protein Therapeutics Market Overview
  • 29.2. Africa Plasma Protein Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Plasma Protein Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Plasma Protein Therapeutics Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Plasma Protein Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Plasma Protein Therapeutics Market Competitive Landscape
  • 30.2. Plasma Protein Therapeutics Market Company Profiles
    • 30.2.1. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Grifols SA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. China Biologic Products Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Plasma Protein Therapeutics Market Other Major And Innovative Companies

  • 31.1. Kedrion SpA
  • 31.2. LFB SA
  • 31.3. Emergent BioSolutions Inc.
  • 31.4. Reliance Life Sciences Private Limited
  • 31.5. ADMA Biologics Inc.
  • 31.6. Prothya Biosolutions BV
  • 31.7. Bio Products Laboratory Ltd.
  • 31.8. Biotest AG
  • 31.9. Taibang Biological Group Co Ltd
  • 31.10. Octapharma Plasma Inc.
  • 31.11. New York Blood Center
  • 31.12. Green Cross Corporation
  • 31.13. China National Biotec Group Company Limited
  • 31.14. Kamada Ltd.
  • 31.15. Australian Red Cross Lifeblood

32. Global Plasma Protein Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plasma Protein Therapeutics Market

34. Recent Developments In The Plasma Protein Therapeutics Market

35. Plasma Protein Therapeutics Market High Potential Countries, Segments and Strategies

  • 35.1 Plasma Protein Therapeutics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Plasma Protein Therapeutics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Plasma Protein Therapeutics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer